Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents
Tweet
Share
E-mail
FILE PHOTO: Pfizer company logo is seen at a Pfizer office in Puurs, Belgium, December 2, 2022. REUTERS/Johanna Geron/File Photo
LONDON (Reuters) -Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's High Court.
Pfizer and BioNTech had filed their lawsuit in September 2022 over patents relating to messenger RNA (mRNA) technology, which underpins Pfizer and BioNTech's COVID-19 vaccine.
Tuesday's ruling relates to the London leg of Pfizer, BioNTech and CureVac's global legal battle, which also involves litigation in the United States and Germany.
Pfizer and BioNTech are separately involved in a case with Moderna over their rival COVID-19 vaccines.
The High Court ruled in that case in July that one of Moderna's mRNA patents was valid and Pfizer and BioNTech's Comirnaty vaccine had infringed it. Pfizer and BioNTech have been granted permission to appeal against that decision.
(Reporting by Sam Tobin; Editing by Sachin Ravikumar and Sarah Young)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- China's 'Lipstick King' confronts slower growth, AI disruption in livestream shopping
- Tesla's supervised self-driving system often misreads speed limits, Belgian safety group finds
- Barry Diller's People withdraws bid for MGM Resorts
Create E-mail Alert Related Categories
ReutersSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
